An underground market for unlicensed weight-loss drugs is being driven by social media fitness personalities and vendors on messaging platforms, according to new investigations.
Investigational Drug Acquiring Popularity Via Social Media
The experimental drug, which remains in clinical trials, is being advertised by online personalities for its supposed weight-reducing effects. Followers are urged to message these accounts directly for supplier links, while also obtaining discount codes.
Thriving Commerce on Social Networks
Additionally, a flourishing trade exists on messaging services, where communities with thousands of participants share comparison images, injection guides and claims of next-day UK delivery. Sellers market the substance there before redirecting buyers to other platforms for transactions.
Learning About Retatrutide
Retatrutide is an investigational injectable created by US drugmaker Eli Lilly. The treatment targets three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials suggest it could help patients reduce up to a quarter of their body weight. Referred to as the “triple G”, the substance is being hailed online as the successor to Ozempic.
Medical Experts Voice Worries
However, physicians and pharmacists have cautions that the sale of what remains an unlicensed medication in the UK is a cause for concern and could result in individuals administering products of unknown origin.
Some professionals stated the popularity for retatrutide could be connected to the increasing price of approved slimming treatments such as Mounjaro.
Legal Status and Implementation
Selling the unapproved drug on social media or messaging apps is prohibited in the United Kingdom, as it is an unapproved drug that cannot be promoted or supplied for personal consumption under the Human Medicines Regulations 2012.
Several content creators try to circumvent the rules by calling to the substance as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted drug, but advertising and distribution can still breach medicines, advertising, and consumer regulations, potentially leading to penalties, legal action or prison.
Service Response and Material Elimination
According to the social media company, the service has removed problematic material and prohibited associated hashtags and search suggestions. The company said it was committed to keeping the platform secure and investing in strengthening compliance measures.
Online Marketplace Activities
Research also discovered groups with up to 9,000 members marketing the experimental drug using the platform's built-in discovery tool, which functions like a public directory. Typing “retatrutide” instantly brings up groups with numerous of members, filled with photos of slimming results, positive reviews and detailed guides for preparing or injecting at home.
After minutes of entering one community, a vendor shared contact information, where most purchases take place. The seller provided an instruction manual and guaranteed shipping within 48 hours. When questioned whether the substance was authentic, one seller responded: “You can’t be sure.” Another provided a photo of a alleged laboratory certificate. None asked about body mass, health issues or previous experience.
Item Details and Costs
Inside these groups, posts display black plastic packages with Royal Mail stickers, stating to include fresh supplies. One message read: “It took eight of us to load them this morning.”
Buyers can select between dry substance containers, mixed at home with purified liquid, or pre-filled pens usually sold at 160 pounds for 20mg. When asked how long a injector should be used, vendors give conflicting responses ranging from a several days to “depends on your body”.
Platform Moderation and Safety Measures
A spokesperson for the messaging service stated it actively monitored dangerous material on its service including material that encouraged the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.
Medical Professional Warnings
“People are injecting substances they can’t verify. Even if the research behind this drug is valid, these online products may not include what they advertise,” stated Jason Murphy, the head of pharmacy at a pharmacy service.
Dr Crystal Wyllie of an online medical service connected the surge in demand to recent price rises for approved weight-loss medications such as Mounjaro. “With costs increasing, patients are turning to social media. But fake injections are extremely dangerous. You can’t be certain what’s inside or whether the environment they were made in was clean,” she said.
Her team has previously seen individuals injured by self-injection from unconfirmed suppliers. “We recognize the frustration, but buying from Telegram or communication platforms is taking chances with your health,” stated the doctor. “These materials could be impure or improperly measured.”
Manufacturer Position
A representative from Eli Lilly said retatrutide was in third stage clinical trials and had not been reviewed or approved by any government authority anywhere in the world. “Consequently at this point no one can sell [it] for personal consumption,” they said, adding that any item “misleadingly claiming itself as a company investigational substance not yet approved … may expose patients to potentially serious health risks”.
